retatrutide phase 3 triumph just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist posted two major readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Retatrutide Achieves Up to 30.3%

While still highly effective, it falls short of the results seen with tirzepatide

Ozempic, Wegovy, Mounjaro, and Zepbound all belong to a class of drugs called glucagon-like peptide-1 receptor agonists, or GLP-1 receptor agonists

In the United States, tirzepatide is sold under two brand names

While the mechanisms of GLP-1 medications are well understood, reliable outcomes below validated dosing thresholds have not been established in clinical trials

Average Patient Lifetime Value : If your acquisition cost is $200-300 (via platform or efficient marketing), thats a 3:1 to 5:1 ROI solid for any medical practice

GLP-1s work by slowing stomach emptying, increasing feelings of fullness, and reducing appetite